Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xinjikang granules
- Development stage
- Unknown
- Lead developer
- Shanghai Pharmaceuticals Group Qingdao Growful Pharmaceutical
- Administration
- Oral
01
Overview
Xinjikang Granules is a Traditional Chinese Medicine (TCM) manufactured by Shanghai Pharmaceuticals Group Qingdao Growful Pharmaceutical. It is primarily indicated for the treatment of viral myocarditis, particularly cases characterized by Qi and Yin deficiency. The formulation is designed to tonify Qi, nourish Yin, and activate blood circulation to resolve stasis. Clinical applications focus on protecting the myocardium from inflammatory damage, improving cardiac function, and alleviating symptoms such as palpitations, chest tightness, and shortness of breath. As a multi-herb granule formulation, it is typically administered orally.
- Brand names
- Xinjikang Granules
- Other names
- 心肌康颗粒Xinjikang Keli
Beyond the preview
Go deeper on xinjikang granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xinjikang granules.